e-Therapeutics PLC - Oxford-based drug discovery platform - Says in vitro assays testing small molecule compounds have confirmed in silico predictions, and company has identified "a clear mechanism, target and clinical stage compounds".
"These compounds are active against GRP94 and have anti-inflammatory and anti-viral activity against Sars-CoV-2. This activity generalises to other alpha and beta coronaviruses and is expected to be generically applicable, raising the prospect of utility against both existing coronaviruses that cause serious disease such as SARS and MERS and against new emergent strains of coronavirus," says e-Therapeutics.
The clinical stage compounds identified have an established safety profile and these, along wiht other selective compounds sharing this target, could be "rapidly deployed" into clinical trials to treat patients with serious Covid-19.
"e-therapeutics' platform has the ability to start with any biological process of relevance to disease and to identify compounds and targets that can modulate that process in a therapeutic setting. This data set is a strong validation of our platform and the network biology approach to drug discovery," says Chair & Chief Executive Ali Mortazavi.
Current stock price: 15.75 pence
Year-to-date change: up more than fivefold from 3.10p
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
